Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
QDEL 
Quidel Corporation (QDEL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/20/2025: QDEL (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Year Target Price $47.14
Year Target Price $47.14
| 3 | Strong Buy |
| 2 | Buy |
| 2 | Hold |
| 0 | Under performing |
| 1 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit -15.14% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/20/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.95B USD | Price to earnings Ratio - | 1Y Target Price 47.14 |
Price to earnings Ratio - | 1Y Target Price 47.14 | ||
Volume (30-day avg) 8 | Beta 0.09 | 52 Weeks Range 23.77 - 49.45 | Updated Date 06/30/2025 |
52 Weeks Range 23.77 - 49.45 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.23 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -12.97% | Operating Margin (TTM) 7.03% |
Management Effectiveness
Return on Assets (TTM) 1.12% | Return on Equity (TTM) -11.38% |
Valuation
Trailing PE - | Forward PE 11.82 | Enterprise Value 4519458924 | Price to Sales(TTM) 0.71 |
Enterprise Value 4519458924 | Price to Sales(TTM) 0.71 | ||
Enterprise Value to Revenue 1.63 | Enterprise Value to EBITDA 15.67 | Shares Outstanding 67625904 | Shares Floating 60875457 |
Shares Outstanding 67625904 | Shares Floating 60875457 | ||
Percent Insiders 0.88 | Percent Institutions 112.4 |
Analyst Ratings
Rating 3 | Target Price 47.14 | Buy 2 | Strong Buy 3 |
Buy 2 | Strong Buy 3 | ||
Hold 2 | Sell 1 | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Quidel Corporation
Company Overview
History and Background
Quidel Corporation, founded in 1979, initially focused on developing rapid diagnostic solutions. It evolved from producing pregnancy tests to a broad portfolio of diagnostic products for infectious diseases, cardiac health, and autoimmune diseases. In 2021, Quidel acquired Ortho Clinical Diagnostics, significantly expanding its global presence and product offerings. In May 2023, the company officially changed its name to QuidelOrtho Corporation.
Core Business Areas
- Point-of-Care Diagnostics: Develops and manufactures rapid diagnostic tests for use in physician's offices, hospitals, and other healthcare settings.
- Molecular Diagnostics: Offers molecular diagnostic solutions for detecting and identifying infectious diseases using PCR-based technology.
- Immunoassay: Provides immunoassay products for a wide range of diagnostic applications, including autoimmune disease and cardiac markers.
- Transfusion Medicine: Supplies products and solutions for blood banks and transfusion centers.
- Laboratory Solutions: Provides a broad range of diagnostic equipment, reagents, and consumables for clinical laboratories.
Leadership and Structure
Douglas Bryant is the Chairman, President, and CEO of QuidelOrtho. The company operates with a functional organizational structure, with various departments responsible for research and development, manufacturing, sales and marketing, and finance.
Top Products and Market Share
Key Offerings
- Sofia 2 Fluorescent Immunoassay Analyzer: A point-of-care diagnostic system for rapid detection of influenza A and B. Competitors include Roche, Abbott, and Siemens Healthineers. Market share data is not readily available.
- Lyra Direct SARS-CoV-2 Assay: A molecular diagnostic test for detecting SARS-CoV-2. Roche, Abbott, and Thermo Fisher Scientific are major competitors. Market share data is not readily available.
- Triage MeterPro: A point-of-care platform for cardiovascular, toxicology, and coagulation testing. Competitors include Roche, Siemens Healthineers. Market share data is not readily available.
Market Dynamics
Industry Overview
The in vitro diagnostics market is experiencing growth due to an aging population, increasing prevalence of chronic diseases, and growing demand for point-of-care diagnostics. Technological advancements, such as molecular diagnostics and next-generation sequencing, are driving innovation in the industry.
Positioning
QuidelOrtho is a key player in the in vitro diagnostics market, with a strong presence in point-of-care and molecular diagnostics. Its competitive advantages include its established brand reputation, broad product portfolio, and global distribution network.
Total Addressable Market (TAM)
The global in vitro diagnostics market is projected to reach hundreds of billions of dollars. QuidelOrtho is positioned to capture a significant share of this market through its diverse product offerings and strategic acquisitions.
Upturn SWOT Analysis
Strengths
- Strong brand reputation
- Broad product portfolio
- Global distribution network
- Innovative diagnostic technologies
- Experienced management team
Weaknesses
- Dependence on certain key products
- Exposure to regulatory risks
- Integration challenges related to the Ortho Clinical Diagnostics acquisition
- High debt levels following the acquisition
Opportunities
- Expanding into emerging markets
- Developing new diagnostic tests for unmet medical needs
- Acquiring complementary businesses
- Leveraging the Ortho Clinical Diagnostics acquisition to expand its product offerings and global reach
Threats
- Intense competition from established players
- Price pressures from healthcare providers
- Technological obsolescence
- Changes in regulatory requirements
- Economic downturn
Competitors and Market Share
Key Competitors
- RHHBY
- ABT
- SIEMENS
- BDX
Competitive Landscape
QuidelOrtho faces intense competition from larger, more diversified players in the in vitro diagnostics market. Its competitive advantage lies in its focus on point-of-care and molecular diagnostics, as well as its strong brand reputation. The company needs to successfully integrate Ortho Clinical Diagnostics and leverage its combined product offerings to compete effectively.
Major Acquisitions
Ortho Clinical Diagnostics
- Year: 2022
- Acquisition Price (USD millions): 6000
- Strategic Rationale: Expanded global presence, broadened product portfolio, and enhanced manufacturing capabilities.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is hard to isolate based on the merger.
Future Projections: Future growth projections are based on analysts' estimates and are subject to change.
Recent Initiatives: The Ortho Clinical Diagnostics acquisition is a major strategic initiative aimed at expanding the company's global reach and product offerings. The company is focused on integrating Ortho Clinical Diagnostics and realizing synergies from the acquisition.
Summary
QuidelOrtho is a significant player in the diagnostics industry, boosted by the acquisition of Ortho Clinical Diagnostics. The integration and debt management will be crucial. The company has strong products but faces intense competition from larger, diversified corporations, meaning innovation and market expansion are crucial for future success. Investor confidence hinges on successful integration and execution of strategic initiatives and sustained market share retention.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
- Industry Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data is estimated and may not be precise. Financial data and analysis are based on available information and are subject to change. Past performance is not indicative of future results.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Quidel Corporation
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 1991-02-01 | President, CEO & Director Mr. Brian J. Blaser | ||
Sector Healthcare | Industry Medical Devices | Full time employees 6600 | Website https://www.quidelortho.com |
Full time employees 6600 | Website https://www.quidelortho.com | ||
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point of Care business unit provides instruments and tests to provide rapid results across a continuum of POC settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.